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Abstract
Objective—To evaluate the cost-effectiveness of Internet-based cognitive-behavioral therapy for 
bulimia nervosa (CBT-BN) compared to face-to-face delivery of CBT-BN.
Methods—This paper is a planned secondary analysis of data from a randomized clinical trial 
(RCT). Participants were 179 adults (85% female, M age = 28 years) meeting DSM-IV criteria 
randomized to group face-to-face or group Internet-based CBT-BN for 16 sessions over 20 weeks. 
The cost-effectiveness analysis was conducted from a third party-payor perspective, and a partial 
societal perspective analysis was conducted to investigate cost-utility (i.e., cost per gain in quality-
adjusted life years) and patient out-of-pocket travel-related costs. Net health care costs were 
calculated from protocol and non-protocol health care services using third-party payor cost 
estimates. The primary outcome measure in the clinical trial was abstinence from binge eating and 
purging, and the trial start and end dates were 2008 and 2016.
Results—The average cost per abstinent patient at post-treatment was $7,757 (95% CI = $4,515, 
$13,361) for face-to-face and $11,870 (95% CI = $6,486, $22,188) for Internet-based, and at 1-
year follow-up was $16,777 (95% CI = $10,298, $27,042) for face-to-face and $14,561 (95% CI = 
$10,165, $21,028) for Internet-based CBT-BN. There were no statistically significant differences 
between treatment arms in cost-effectiveness or cost-utility at post-treatment or 1-year follow-up. 
Out-of-pocket patient costs were significantly higher for face-to-face than Internet-based therapy.
Conclusions—Third-party payor cost-effectiveness of Internet-based CBT-BN is comparable 
with that of an accepted standard. Internet-based dissemination of CBT-BN may be a viable 
alternative for patients geographically distant from specialist eating disorder services who have an 
unmet need for treatment.
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There is an urgent clinical need to make effective management of bulimia nervosa (BN) 
more widely available. Epidemiological data suggest that 1.5% of women will develop 
bulimia nervosa in their lifetime.1 The standardized mortality rate for patients with BN is 
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twice as high as the annual death rate from all causes.2 BN is a markedly distressing, time-
consuming illness with substantial social, occupational, and financial impairments.3 The 
impacts place the illness as a significant cause of burden of disease, particularly among 
young adult women.4
Studies on long-term course suggest that BN may persist throughout adulthood without 
treatment. In a community study of Finnish female twins, 45% of individuals still had the 
illness five years after onset, and fewer than a third of cases had been detected by health 
professionals.5 Other estimates suggest that fewer than 1 in 5 women with an eating disorder 
receive professional help.6 Evidence-based treatments have been developed and the best-
supported treatment is cognitive-behavioral therapy specifically tailored for bulimia nervosa 
(CBT-BN).7 The efficacy of CBT-BN has been demonstrated in many modes of delivery 
including individual therapy, group therapy, Internet-based treatment, and other formats.7 
However, the accessibility of CBT-BN is a major issue because it is generally provided only 
by highly trained specialized eating disorder practitioners in urban-based settings; 
furthermore, this treatment is not widely distributed, even in urban settings. Informing 
efforts to disseminate treatment is therefore a public health priority.
In addition to accessibility, cost of eating disorder treatment is a concern, in part as eating 
disorders are perceived to be difficult and expensive to treat. The setting of limited health 
care resources also makes cost of treatment an issue of interest to third party payors. 
Increasingly, studies that examine the clinical effectiveness of eating disorder treatment also 
attend to the cost-effectiveness of the evaluated interventions.8 One way to improve the cost-
effectiveness of treatments is to make them more effective, but changes to treatment delivery 
that lower costs also have potential to improve cost-effectiveness.
E-health interventions for eating disorders including Internet-based treatment have recently 
proliferated.9 In studies of Internet-based CBT, efficacy has been demonstrated, and rates of 
binge-purge abstinence have ranged from 14 to 37% at post-treatment and from 30 to 39% at 
follow-up.10–12 E-health facilitates access among individuals with geographical and other 
practical constraints, or individuals reluctant to attend face-to-face psychotherapy due to 
stigma, shame, or social anxiety.13 Improving access to effective care is likely to improve 
health outcomes and mitigate long-term morbidity. However, no studies have examined 
whether Internet-based CBT-BN is a cost-effective alternative to standard face-to-face CBT-
BN. Hence, this study aimed to investigate this question. The hypotheses were that Internet-
based CBT-BN would be at least as cost-effective as face-to-face CBT-BN, with 
effectiveness measured in terms of abstinence from binge eating and purging and 
improvement in quality of life.
Method
Participants
Participants in the current study comprised 179 adults randomized to face-to-face CBT-BN 
(n = 90) and Internet-based CBT-BN (n = 89). The trial was registered on ClinicalTrials.gov 
(identifier: NCT00877786) and has been published.12 The hypothesis in the non-inferiority 
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trial was that the proportion achieving abstinence in Internet-based CBT-BN would be non-
inferior to face-to-face CBT-BN.
Briefly, the RCT took place at two sites, the University of North Carolina at Chapel Hill 
(UNC) and at Western Psychiatric Institute and Clinic of the University of Pittsburgh 
Medical Center (UPMC). Participants met inclusion criteria of Diagnostic and Statistical 
Manual Fourth Edition (DSM-IV)14 bulimia nervosa, ≥18 years, English-speaking, with 
reliable and private Internet access. Individuals were ineligible if they had a medical 
problem or developmental disability that would interfere with treatment, alcohol/drug 
dependence, severe suicidal ideation, schizophrenia, psychosis, bipolar disorder, or were 
pregnant. The study was conducted using an intent-to-treat approach. From the 196 in total 
randomized, only individuals who withdrew consent (n = 13), were terminated (n = 3; i.e., 
had a change in status during the study and met exclusion criteria), and had a missing 
baseline assessment (n = 1) were excluded. The study was approved by the institutional 
review boards at UNC and UPMC.
Procedures
Details of the design have been published previously.12, 15 Briefly, participants were 
randomized to group face-to-face or group Internet-based CBT-BN. A group modality was 
chosen to make intervention feasible in the study contexts. Group and individual CBT are 
similarly effective, although some research has found that individual CBT is associated with 
higher abstinence.7 Each treatment arm included sixteen 1.5 hour sessions delivered over 20 
weeks. Patients in face-to-face CBT-BN had in person group sessions at the treatment site. 
Patients in Internet-based CBT-BN convened with the therapist via an online chat group 
accessed with an anonymous username and password; the chat room was text-based 
messages only.
Measures
Outcome—The primary effectiveness outcome was abstinence from binge eating/purging 
over the past 28 days measured with the Eating Disorder Examination (EDE)16 at post-
treatment and 1-year follow-up. The abstinence proportions used were those reported in the 
outcome paper12: at post-treatment, individuals with missing data were conservatively 
assumed to be non-abstinent in the study, and at 1-year follow-up, in light of attrition, 
abstinence was estimated with multiple imputation. Cost-effectiveness was calculated as the 
cost of treatment per abstinent patient.
The secondary effectiveness outcome was quality-adjusted life years (QALYs), measured via 
the Short-Form Health State Classification (SF-6D), which is derived from the SF-36, 
administered at baseline, post-treatment, and 1-year follow-up. The SF-6D is a utility-based 
measure of health-related quality of life17 and has good validity.18 The algorithm gives a 
value ranging between 0 (death) and 1 (perfect health). Cost-utility was calculated as the 
cost per QALY gained. QALY gain refers to the increase in QALYs before and after 
treatment; one QALY gain means that the person has gained one year in perfect health.
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Intervention—Psychotherapy visits were derived from electronic attendance records. The 
patient was required to present at either the face-to-face or Internet-based session (i.e., 
securely log in) for a visit to be counted.
Nonprotocol healthcare—Patient encounters with health services that were not part of 
the CBT-BN trial intervention are considered to be nonprotocol costs and include, for 
instance, visits to primary care professionals and prescription medications. Nonprotocol 
healthcare was calculated for posttreatment and 1 year follow-up, using the McKnight 
Follow-up of Eating Disorders (M-FED). The M-FED was administered to participants at 
post-treatment, 3-, 6- and 12-months after treatment. The M-FED was developed for the 
McKnight Foundation sponsored studies of anorexia nervosa treatment,19 bulimia nervosa 
treatment,20–23 and a four year longitudinal follow-up study of eating disorders.23 The 
instrument captures a wide range of healthcare services: medical monitoring, medication 
management, individual therapy, group therapy, family/couples therapy, nutritional 
management, weight management, partial hospitalization, inpatient hospitalization, and 
emergency room use. The instrument was developed from the Longitudinal Interval Follow-
Up Evaluation24 with additional questions adapted from the Structured Clinical Interview 
for DSM-IV (SCID)25, and specific questions developed for measuring medical and mental 
health utilization. In this trial, only the utilization portion was employed. The version of the 
M-FED used in this trial was revised based on experience using it to measure medical and 
mental health utilization in other trials (R01 MH 59234; R01 MH 058821; R01 DK 61912; 
and currently 2 R01 MH 058820).
Costs
Inflation did not need to be accounted for as all cost estimates were based on costs in 2013 
(i.e., the year the trial treatment phase closed).
Intervention costs—The cost of CBT-BN in each condition was captured by assigning 
the billing charge for group therapy in the 2013 Current Procedural Terminology (CPT).26 
The total per-person cost was based on the number of sessions attended by each patient.
Nonprotocol healthcare costs—Patient consumption of healthcare that was not in the 
study protocol was costed. For assignment of hospital inpatient costs, Diagnosis Related 
Grouping (DRG) diagnoses were derived from the reasons given by individuals for hospital 
admissions and DRG cost figures were obtained from the Center for Medicare and Medicaid 
Services (CMS) website (www.cms.gov). For outpatient and emergency room utilization, 
procedure codes were assigned using the CPT Code Book, then costs from the CMS website 
for these services were calculated. For medication usage, lowest average wholesale price 
was obtained from the Red Book, which is a drug pricing compendium aiding pharmacy 
operations.27 Costs for medication management visits were captured from the CPT Code 
Book.
Gas and travel time costs—Distance traveled to the clinic for face-to-face CBT-BN was 
based on self-report. Average miles per gallon (MPG) was assumed from US Chamber of 
Commerce-Institute for 21st Century Energy data (17 miles per gallon), and average cost of 
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gas per gallon was assumed from US Energy Information Administration 2013 data ($3.50 
North Carolina, $3.56 Pennsylvania). Per-person gas cost was calculated as: (return 
distance / average MPG) × average cost per gallon × number of sessions attended. Travel 
time was obtained from self-report and hourly wage was estimated from US Census Bureau 
2013 per capita annual income ($13.17/hour North Carolina, $14.84/hour Pennsylvania). 
The per-person cost of time to travel to the clinic was calculated as: travel time (return travel 
time included) × hourly wage × number of sessions attended.
Statistical Analysis
Analyses were performed in accordance with the intent-to-treat principle and conducted with 
SAS 9.4. The primary perspective for this study was a third-party payor perspective, using 
direct medical costs. The rationale was that direct costs have greater impact on third-party 
payor decisions than societal perspective costs. Additionally, there is a widespread view that 
eating disorder treatment is expensive, as such, cost considerations play a prominent role in 
third-party payor decisions about coverage of care, at least in the United States.
Data management—There were missing data at post-treatment and 1-year follow-up due 
to attrition. When imputing missing data, the pattern of missing data is more important than 
the amount missing. Missing data were assumed to be missing at random (MAR) and were 
imputed with the expectation maximization algorithm, which produces asymptotically 
unbiased estimates using full-information maximum-likelihood estimation.
Third-party payor perspective—The average cost-effectiveness ratio was calculated for 
each treatment arm, which is the average cost of treatment for all subjects in an arm divided 
by the proportion achieving abstinence in that arm. Because the sample mean for cost data 
was not normally distributed, the bootstrapped mean (and 95% confidence limits) is 
provided. Bootstrapping is a non-parametric procedure that simulates the normal distribution 
of the mean and addresses statistical uncertainty in the cost and effect estimates. Bootstrap 
resampling was done with random replacement using 10,000 simulated samples. The mean 
cost-effectiveness ratio gives a base case estimate of the cost per abstinent subject.
Societal perspective—The analysis is limited by a lack of inclusion of productivity 
losses, hence it is a partial societal perspective analysis. Two analyses were conducted. 
Firstly, we examined change in health-related quality of life from baseline to post-treatment 
and baseline to 1-year follow-up to give a base case estimate of dollars per QALY gained for 
each treatment arm. The QALYs were calculated by multiplying the SF-6D utility score by 
the time spent in that health state. The conventionally accepted threshold for a cost-effective 
treatment is $50,000/QALY, although some have advocated for $110–160,000/QALY in the 
United States given the greater economic output.28 For the purposes of this study, values 
below the $50,000 QALY threshold were considered cost-effective. Bootstrap estimates 
were used to generate the mean estimate and to evaluate uncertainty in cost per QALY gain 
estimates using 10,000 simulated samples drawn with replacement. The second analysis 
allowed for inclusion of the cost of patient automobile fuel and time to travel to 
appointments, which would differ between face-to-face and Internet-based CBT-BN.
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Sensitivity analyses—For the societal perspective analysis, it is realistic to consider that 
patients in Internet-based treatment might be charged a software cost. It is routine to exclude 
software development costs from analysis. However, to be conservative, we factored in a 
cost of $50 per person based on the assumption that the software would be non-commercial, 
and that this nominal amount would cover administrative tasks such as processing orders and 
updating/fixing bugs.
Results
The 179 participants were mostly female, employed, and college graduates (Table 1). The 
mean number of treatment sessions was 8 (SD = 5) in both conditions. Treatment was 
completed (≥75% of sessions) by 43% (n = 39) in face-to-face and 39% (n = 35) in Internet-
based CBT-BN. Costs for patients are shown in Table 2. The average total cost for health 
care utilization (including protocol and non-protocol costs) was $1,473 and $1,470 at post-
treatment and $4,142 and $4,131 at 1-year follow-up, for face-to-face and Internet-based 
CBT-BN, respectively. Recall, based on the design of the study, that the posttreatment cost 
involves a time frame of ~5 months and includes protocol and nonprotocol costs, and that 
the follow-up covers a time frame of ~12 months and includes nonprotocol costs only.
Full details of the trial and clinical outcomes have been reported.12 Briefly, with respect to 
the primary outcome of abstinence, Internet-based CBT-BN was inferior to face-to-face 
CBT-BN at post-treatment but non-inferior at 1-year follow-up. Abstinence was attained by 
21% (18/90) and 14% (12/89) at post-treatment, and 26% (18/90) and 30% (26/89) at 1 year-
follow-up, in face-to-face and Internet-based CBT-BN, respectively. QALY gain is shown in 
Table 3. Over the course of treatment, participants in each group gained on average ~1 week 
of full health. At the end of one year, those in face-to-face had gained 4 weeks of full health 
and those in Internet-based gained 5 weeks. The clinical significance of these differences are 
small. It is important to note that the time horizon for measuring QALY gains (1 year) is a 
conservative one. The QALY gains from treatment for BN likely extend beyond 1 year, as 
BN symptoms if untreated typically last for years, so the QALY gains from treatment likely 
also accumulate over years and would thus be greater than this conservative analysis 
suggest.”
Third-Party Payor Analysis
Average cost-effectiveness ratios indicating the cost per abstinent individual for each 
treatment arm are shown in Table 3. At post-treatment, the cost effectiveness ratio was 
$7,757 for face-to-face and $11,870 for Internet-based CBT-BN. At 1-year follow-up, the 
cost-effectiveness ratios were $16,777 for face-to-face and $14,561 for Internet-based. The 
confidence limits for each treatment arm overlapped at post-treatment and at 1-year follow-
up signifying that there were no statistically significant differences in cost-effectiveness 
between the treatment arms at either time point. Figure 1 shows a scatterplot of bootstrapped 
cost and effect pairs presented on the incremental cost-effectiveness plane. The axes 
represent differences between the treatment arms in costs and effects: negative cost 
differences indicate that Internet-based CBT-BN had a lower cost-estimate than face-to-face 
CBT-BN; and positive effectiveness/utility differences mean that Internet-based CBT-BN is 
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more effective than face-to-face CBT-BN. At post-treatment, the majority of estimates lie in 
the north-west quadrant (indicating that Internet-based CBT-BN is more costly, less effective 
than face-to-face CBT-BN) and south-west quadrant (indicating that Internet-based CBT-BN 
is less costly, less effective), and at follow-up, the majority lie in the north-east quadrant 
(indicating that Internet-based CBT-BN is more costly, more effective than face-to-face 
CBT-BN) and south-east quadrant (indicating that Internet-based CBT-BN is less costly, 
more effective). The 95% confidence ellipse contains the origin in its interior at post-
treatment and 1-year follow-up, so there are no statistically significant differences in cost-
effectiveness between conditions.
Societal Perspective Analysis
At post-treatment, the cost-utility ratio was $73,618/QALY for face-to-face and $59,540/
QALY for Internet-based CBT-BN, and at 1-year follow-up, $56,801/QALY for face-to-face 
and $38,715/QALY for Internet-based CBT-BN (Table 3). Figure 1 shows bootstrapped cost 
and utility pairs on the incremental cost-effectiveness plane. The 95% confidence ellipse 
contains the origin in its interior, so there are no statistically significant differences between 
conditions in cost-utility at posttreatment or 1-year follow-up. Regarding practical 
significance, according to the pre-determined threshold of $50,000/QALY, Internet-based 
CBT-BN was cost-effective at 1-year follow-up. At post-treatment, neither face-to-face or 
Internet-based CBT-BN were cost-effective according to the practical significance threshold, 
neither was face-to-face treatment at follow-up.
The average distance travelled to the clinic by face-to-face patients was 17 miles (SD = 23) 
and the average trip time was 28 minutes (SD = 23). Out-of-pocket costs of gas and travel 
time to attend therapy were statistically significantly different between treatment arms. At 
post-treatment, the average total cost was $178 (95% CL [$127, $240]) for face-to-face and 
nil for Internet-based participants.
Sensitivity analysis
Out-of-pocket costs were $50 (95% CL [$50, $50]) for Internet-based including software 
versus $178 (95% CL [$127, $240]) for face-to-face CBT-BN. Patients in Internet-based 
therapy still had significantly lower out-of-pocket costs when the software was included.
Discussion
Face-to-face and Internet-based CBT-BN had similar cost-effectiveness, measured as the 
cost per abstinent patient. Cost-utility, measured as the cost per gain in QALYs was also 
comparable across intervention arms. Patient out-of-pocket costs were significantly lower in 
Internet-based treatment due to the absence of travel-related costs.
Although Internet-based CBT-BN was slower to achieve its effects than face-to-face CBT-
BN,12 there were no significant differences in cost-effectiveness or cost-utility at post-
treatment or 1-year follow-up. This finding has implications for the dissemination of CBT-
BN. Geographically remote individuals are typically at a disadvantage as they lack the 
eating disorder services of their urban counterparts. Waiting lists could be reduced by being 
able to provide treatment at a time and location convenient to the patient (i.e., work lunch 
Watson et al. Page 8













hour). Further delivery formats that have had support include CBT delivered via 
telemedicine29 and self-help CBT-BN with Internet support.10 Given the lack of difference 
in cost-effectiveness or cost-utility, third-party payors are encouraged to provide cover for 
empirically-supported technological solutions that increase treatment access.
Some individuals are deterred from seeking face-to-face psychotherapy because of personal 
barriers including embarrassment, fear of stigma, out-of-pocket costs, social anxiety, and 
inconvenience.30 Internet-based CBT-BN may be a cost-effective way of improving access 
to care among individuals with personal barriers. Internet-based treatment may offer more 
privacy than setting foot in a clinic in the community. Participants in the Internet-based arm 
chose the location they accessed treatment (i.e., home) and logged in to the group chat 
session with an anonymous username and password that concealed their identity from other 
group members. Internet-based CBT-BN was associated with out-of-pocket cost savings.
There were modest gains in QALYs at post-treatment, which is not surprising given the short 
time-frame, and at 1-year follow-up. The QALY measure showed less sensitivity than the 
treatment effect measure of abstinence. Results supported the cost-utility of Internet-based 
CBT-BN at 1-year follow-up, but not face-to-face CBT-BN according to the conventionally 
used threshold, although no statistically significant differences between the two treatment 
arms were found. Although scores increased over time, the mean baseline, post-treatment, 
and 1-year follow-up SF-6D utility scores in each condition fell significantly below reported 
norms (~0.8 for this age group),31, 32 highlighting the toll of bulimia nervosa. The choice of 
a cost-utility threshold is a value judgment that depends on several factors; some decision-
makers may conclude that these two interventions are reasonably cost-effective. The 
estimates fell well within the limit of US$160,000 per year, above which few decision-
makers would find acceptable. The analyses were performed from a partial societal 
perspective, as costs of productivity loss due to illness were not captured.
Abstinence rates seem to increase in the Internet-based arm, while decreasing in the face-to-
face arm between post-treatment and 1 year, while costs are comparable in both groups. It 
could be that individuals in the Internet-based arm were reviewing therapy materials more 
frequently after treatment than those in face-to-face, as they had online access to materials.
This study has important strengths, including being the first study known to us to compare 
and calculate the cost-effectiveness of Internet-based CBT-BN vs. face-to-face CBT-BN. 
Strengths also include the rigor of therapy and clinical assessment, and wide range of 
nonprotocol healthcare utilization captured. Several limitations are apparent. Attrition 
increased over the course of the study and at 1-year follow-up the present sample may not 
have been large enough for missing data imputation. Simulation studies suggest that FIML 
imputation in general produces unbiased estimates, however large samples (i.e., 500) may be 
required to reveal the asymptotic distribution when attrition is higher.33 Wider measures of 
societal perspective costs were unavailable. Workplace costs due to productivity losses, and 
further out-of-pocket expenditures by the patient and caregivers (i.e., copayments, 
prescription medications, binge/purge food costs, diet and purging aid costs, child care 
expenses, gas and travel time costs to attend nonprotocol healthcare) are examples. These 
likely constitute an important part of the societal costs, but are more difficult to measure. In 
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addition, carefully tracking some costs (i.e., cost of binge food) might impact symptom 
levels, confounding their accurate measurement in trials. A common argument for studying 
Internet-based interventions is that they are likely to cost less because of savings in clinic 
operating costs (i.e., administrative labor, overheads), but because these costs are not easily 
estimated and because the services that clinics choose to offer are heavily influenced by 
third-party payor decisions, it was deemed most useful to adopt a third-party payor 
perspective for the present study. Most participants lived within readily traveled distances to 
the clinic, so the travel costs underestimate the costs for patients who live further from 
services. Furthermore, many people would simply not access treatment from substantial 
distance. Even so, such individuals would remain at risk for medical complications and 
higher rates of other kinds of medical utilization.
This study supports Internet-based CBT-BN as a comparably cost-effective treatment to an 
accepted standard, face-to-face CBT-BN. Third-party payors are urged to develop and 
implement reimbursement schedules that increase access to effective treatment, and 
therapists and specialist services are encouraged to consider technologically innovative 
models of care.
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Bootstrapped cost and effectiveness estimates for face-to-face versus Internet-based 
cognitive-behavioral therapy for bulimia nervosa (CBT-BN).
The plots at the top show the mean differences in costs and effectiveness on the primary 
outcome measure (Eating Disorder Examination binge and purge abstinence) using 10,000 
bootstrap replicates. The plots at the bottom show the mean differences in costs and utility 
on quality-adjusted life years (QALY) gain using 10,000 bootstrap replicates. Negative cost 
differences indicate that Internet-based CBT-BN had a lower cost estimate than face-to-face 
CBT-BN, and positive effectiveness (or utility) estimates indicate that Internet-based CBT-
BN had a higher abstinence (or QALY gain) estimate than face-to-face CBT-BN. The 
quadrants (clockwise from top right) represent the following scenarios for Internet-based 
CBT-BN compared with face-to-face CBT-BN: (1) more costly and more effective, (2) less 
costly and more effective (ideal), (3) less costly and less effective, and (4) more costly and 
less effective. The ellipse indicates the 95% confidence limits.
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Table 1
Study demographic and baseline characteristics.
Face-to-face
CBT-BN (n = 90)
Internet-based
CBT-BN (n = 89)
Female (%, n) 98 (88) 98 (87)
Age, yrs (M ± SD) 27.5 (9.1) 28.5 (9.3)
White (%, n) 86 (77) 84 (75)
Latino (%, n) 4 (5) 4 (5)
Married/defacto (%, n) 22.2 (20) 19.1 (17)
Employed (%, n) 66.7 (60) 66.3 (59)
College graduate (%, n) 59.6 (53) 51.7 (46)
Body mass index, kg/m2 (M ± SD) 24.2 (4.7) 24.1 (5.7)
Frequency of objective binge eating (M ± SD) 14.1 (12.6) 16.4 (14.9)
Frequency of purging (M ± SD) 26.8 (20.7) 31.7 (34.2)
SF-6D (M ± SD) 0.66 (0.10) 0.66 (0.09)
Note. SF-6D = Short-Form Health State Classification.
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Table 2
Summary of per-subject protocol and nonprotocol treatment costs by treatment arm.
Face-to-face
CBT-BN (n = 90)
M (SD)
Internet-based
CBT-BN (n = 89)
M (SD)
Post 1 yr f/u Post 1 yr f/u
CBT-BN 211 (144) 211 (144) 201 (142) 201 (142)
Physician visits 46 (69) 175 (245) 64 (119) 164 (223)
Medication management 74 (129) 209 (247) 84 (156) 269 (479)
Individual therapy 85 (210) 528 (838) 223 (480) 858 (1076)
Group therapy 14 (66) 32 (109) 17 (58) 44 (144)
Family/couples therapy 8 (30) 21 (78) 29 (177) 73 (317)
Nutrition counseling 33 (116) 82 (205) 15 (46) 47 (96)
Weight management 2 (15) 6 (24) 2 (6) 7 (20)
Partial hospitalization 228 (1276) 423 (2268) 90 (483) 180 (705)
Inpatient 131 (593) 293 (1219) 233 (1218) 345 (1348)
Emergency room 13 (29) 24 (46) 7 (16) 16 (29)
Prescription medication 593 (1180) 1387 (2674) 526 (868) 1477 (1931)
Total $1,473 ($2,021) $4,142 ($5,608) $1,470 ($1,950) $4,131 ($4,046)
Note. Costs are in 2013 US dollars. CBT-BN is a per-protocol cost and all other treatments are non-protocol costs. CBT-BN = cognitive behavioral 
therapy for bulimia nervosa.
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Table 3
Cost and effectiveness of face-to-face and Internet-based cognitive-behavioral therapy for bulimia nervosa 
(CBT-BN)
Face-to-face
CBT-BN (n = 90)
Internet-based
CBT-BN (n = 89)
Post 1 yr f/u Post 1 yr f/u
Cost $1,473 $4,142 $1,470 $4,131
Effectiveness (abstinence) 0.21 0.26 0.14 0.30




$7,757 ($4,515, $13,361) $16,777 ($10,298, $27,042) $11,870 ($6,486, $22,188) $14,561 ($10,165, $21,028)
Average cost-utility 
ratio ($/QALY)
$73,618 ($42,580 $133,815) $56,801 ($34,396, $96,906) $59,540 ($36,990, $96,641) $38,715 ($26,486, $56,739)
Note. Costs are in 2013 US dollars. QALY = quality-adjusted life years. The cost-effectiveness and cost-utility estimates are means and 95% 
confidence limits from bootstrapping analyses with 10,000 samples.
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